Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31085390 | 1.00 | CDC7 (0.53) | CDC7KDRNPC1RAB9AMKNK1 | |
| SCHEMBL30176980 | 0.83 | CDC7 (0.53) | CDC7KDRNPC1RAB9AMKNK1 | |
| SCHEMBL21856670 | 0.83 | CDC7 (0.53) | CDC7KDRNPC1RAB9AMKNK1 | |
| SCHEMBL22655800 | 0.82 | MKNK1 (0.42) | CDC7KDRMKNK1TRPA1TRPM8 | |
| SCHEMBL29536476 | 0.82 | MKNK1 (0.42) | CDC7KDRMKNK1TRPA1TRPM8 | |
| SCHEMBL21856798 | 0.80 | CDC7 (0.53) | CDC7KDRNPC1RAB9AMKNK1 | |
| SCHEMBL21901031 | 0.79 | CDC7 (0.46) | CDC7KDRNPC1RAB9AHTR2C | |
| SCHEMBL31085393 | 0.77 | CSNK2A1 (0.46) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL22655814 | 0.77 | CSNK2A1 (0.46) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL21900969 | 0.75 | CDC7 (0.46) | CDC7KDRNPC1RAB9AMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2024-10-10 | — | — | US | disclosed |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3969440-A1 | CONDENSED TRICYCLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114096542-A | Condensed tricyclic pyrroles as alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885NPC1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.